2025-522216-17-00CompletedPhase 1
A multi-part, adaptive, Phase 1, first time in human study in healthy participants and participants with atopic dermatitis (AD) to assess the safety, tolerability, pharmacokinetics (PK) of single ascending (SAD), multiple ascending doses (MAD) and selected dose of SYX-5219 (AD Participants)
Source: EU CTIS (euclinicaltrials.eu) · Last updated 12 Jun 2026
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 28 (actual)
- First submitted
- 7 Jul 2025
- Start date
- 26 Jan 2026
- Lead sponsor
- Sitryx Therapeutics Limited
- Diseases
- Atopic dermatitis (eczema)
- EU CT number
- 2025-522216-17-00
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 28
- 7 sites in 4 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (7)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Medical Center Comac Medical Ltd. | Sofia | Bulgaria | Completed |
| Charite Universitaetsmedizin Berlin KöR | Berlin | Germany | Completed |
| Goethe University Frankfurt | Frankfurt Am Main | Germany | Completed |
| Medical Center- University of Freiburg | Freiburg im Breisgau | Germany | Completed |
| University Medical Center Hamburg-Eppendorf | Hamburg | Germany | Completed |
| Sanos A/S | Herlev | Denmark | Completed |
| St James's Hospital | Dublin 8 | Ireland | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.